Zanidatamab
Payments companies reported to CMS as associated with Zanidatamab. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Zanidatamab, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Zanidatamab
These are the largest totals companies reported as associated with Zanidatamab. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Mitesh Borad | Scottsdale, AZ | Hematology & Oncology | $12,314.56 |
| Shubham Pant | Houston, TX | Hematology & Oncology | $11,900.00 |
| Deyali Chatterjee | Nashville, TN | Anatomic Pathology & Clinical Pathology | $11,531.36 |
| Rachna Shroff | Tucson, AZ | Hematology & Oncology | $11,455.29 |
| James Harding | New York, NY | Hematology & Oncology | $10,506.03 |
| Sunyoung Lee | Houston, TX | Medical Oncology | $7,668.47 |
| Maen Abdelrahim | Houston, TX | Medical Oncology | $7,500.00 |
| Alexandros Polydorides | New York, NY | Anatomic Pathology | $6,750.00 |
| Andrew Paulson | Dallas, TX | Medical Oncology | $6,129.91 |
| Aatur Singhi | Baltimore, MD | Anatomic Pathology & Clinical Pathology | $3,375.00 |
Prescribed Zanidatamab?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.